Pharma Marketing Network

"Boehringer Ingelheim is a leader in healthcare social media," according to video the company has just recently uploaded to YouTube for the whole world...

FDA seems obsessed with the distribution of reprints by the pharmaceutical industry. In January, 2009, FDA "finalized" its "Good Reprint Practices for the Distribution of...

My friend Rich Meyer, author of World of DTC Marketing Blog, once again has gone on a rant. This time his target is pharma...

According to Cegedim Strategic Data (CSD) -- a provider of healthcare promotional audits -- in the last 6 months of 2013, the global pharma...

In February 2014, FDA released a new draft guidance document entitled "Distributing Scientific and Medical Publications on Unapproved New Uses - Recommended Practices." FDA's...

"Not all available market research is created equal," says Rich Meyer, author of DTC Marketing Blog. According to Meyer, "some research is a must...

This article reviews BI's 'playbook' -- titled 'How pharma TweetChats can drive healthcare innovation' -- which provides detailed insights for planning and delivering successful pharma TweetChats. The authors of the playbook -- Patricia Alves, Social Media Community Manager, and Jaclyn Fonteyne, Social Media Specialist, at BI -- were also interviewed for this article.

This article reviews the FDA's guidance on how pharmaceutical companies can respond to misinformation related to a firm's own FDA-approved or -cleared products when that information is created or disseminated by independent third parties on the Internet or through social media, regardless of whether that misinformation appears on a firm's own forum or an independent third-party forum or website.

This article reviews the FDA's guidance on how pharma marketers must present both benefit and risk information within a

PMN1306-01Issue: Vol. 13, No. 6: June 2014Find other articles in related Topic Areas: eMarketing and ePromotionDirect-to-Consumer (DTC) Advertising & MarketingRegulatory Compliance